ICYMI: Washington’s Role in High Drug Costs — Marketing Exclusivity and “Shadow Pricing”
ICYMI: May 6, 2015 National Journal: Washington’s Interest in Precision… Read More
ICYMI: May 6, 2015 National Journal: Washington’s Interest in Precision… Read More
ICYMI May 5, 2015 The New York Times: Runaway Drug Prices How companies set… Read More
April 28, 2015 Note: Distributing the New York Times article below is not an… Read More
Two-fer ICYMI: Two WSJ Articles Highlight High Drug… Read More
Originally published on AmericanPharmacyNews.com. Read More
Are Skyrocketing Drug Prices Really Needed for Innovation? Amgen’s… Read More
This morning, the National Journal published an article regarding an increase in public concern over the high cost of prescription drugs. The article references CSRxP’s white paper, “Specialty Drug Hyperinflation: The Risk to Patients and the Health Care System.” Read More
Sky-high drug prices have been causing their fair share of consternation among payers lately, and industry watchers have suspected for a while now that Vertex ($VRTX) will stir the pot when its new cystic fibrosis combo--expected to win FDA approval later this year--hits the market. But just how much will payers need to shell out for the new med over time? Prime Therapeutics has some ideas. Read More
Drug retail giant CVS Health Corp. is girding to do battle with pharmaceutical companies over a coming class of cholesterol drugs that CVS says could cost the nation’s health-care system $150 billion a year. Read More
Ever since Obamacare took effect, Republicans have warned of mission creep: that a law bringing more government regulation to health care would eventually morph into single-payer. Read More
A national group of more than 140,000 physicians on Tuesday joined a coalition dedicated to reversing the growing trend of high-cost specialty drugs, which are being blamed for straining the finances of patients, insurance plans and public health coverage programs. Read More
With patients facing more exposure to the cost of revolutionary new medications, the budget President Barack Obama released Monday reopened a debate on whether government should use its buying power to squeeze the pharmaceutical industry for lower prices. Read More